International Journal of Life science and Pharma Reviews (IJLPR)  
International Journal of Life science and Pharma Research (IJLPR)
Pharmaceutical Sciences
Volume 2 Issue 1, January - March 2012    Pages:13-22
Epigenetic Changes And Their Reversal In Cancer

Abhimanyu Kumar Jha, Meenakshi Jha, Vinay Dwivedi, RashmiChandra,Vivek Kumar And , Jagdeep Kaur
[View PDF]
DOI: DOI not available
Cancer is caused by genetic as well as epigenetic changes. Chemotherapy is considered the mainstay of cancer therapy. But multiple side effects of chemotherapy have created a demand for developing other novel and specific targets for cancer therapy. The potential reversibility of epigenetic changes has resulted in the reactivation of epigenetically silenced tumor suppressor genes being an emerging strategy for the treatment of cancer. Epigenetic modifiers like DNA methyltransferase (DNMT) inhibitors and histone deacteylase (HDAC) inhibitors induce the re-expression of epigenetically silenced genes in vitro and in vivo. Moreover, they demonstrate safety and efficacy against neoplastic diseases in clinical trials. DNMT inhibitors like 5-azacytidine and 5-aza-2'-deoxycytidine have recently been approved by FDA for the treatment of myelodysplastic syndrome. Still the mechanism of action behind their clinical efficacy remains unclear. In this review, the different epigenetic changes taking place during tumor progression and their reversal has been discussed.
Keywords: chemotherapy, DNMT, HDAC, epigenetic modifiers
© 2010-2015 IJLPR. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions